Indo US Bio-Tech reported a significant decline in profitability for the quarter ended June 2026, with net profit falling 35.32% to ₹3.04 crore compared to ₹4.70 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this represents a substantial decrease in the company's bottom-line performance despite revenue growth during the same period.
The company demonstrated resilience in its top-line performance, with sales rising 7.21% to ₹32.99 crore in Q1 FY2026 compared to ₹30.77 crore in the same quarter of the previous fiscal year. As reported by Business Standard, this revenue growth indicates the company's ability to maintain market presence and expand its business operations despite the profit decline.
The company's operating profit margin (OPM) declined to 12.03% in Q1 FY2026 from 17.78% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this margin compression contributed to the overall decline in profitability despite the revenue growth achieved during the quarter.
PBDT (Profit Before Depreciation and Tax) decreased by 33% to ₹3.35 crore from ₹5.02 crore in Q1 FY2025, while PBT (Profit Before Tax) fell 36% to ₹3.08 crore compared to ₹4.82 crore in the same period last year. As reported by Business Standard, these figures indicate the company's operational challenges during the quarter that resulted in the overall profit decline despite revenue growth.
